...
首页> 外文期刊>Pharmaceutical patent analyst >Approaches targeting the FGF-FGFR system: a review of the recent patent literature and associated advanced therapeutic agents
【24h】

Approaches targeting the FGF-FGFR system: a review of the recent patent literature and associated advanced therapeutic agents

机译:针对FGF-FGFR系统的方法:近期专利文献和相关的先进治疗剂的综述

获取原文
获取原文并翻译 | 示例

摘要

Fibroblast growth factor receptors (FGFRs) and associated ligands (FGFs) are a family of well-validated targets for therapeutic interventions notably in cancer diseases in relation to their prominent roles in cell growth, survival, differentiation and angiogenesis. This patent review encompasses all different approaches (modulators of FGF or FGFR expression, anti-FGF antibodies, anti-FGFR antibodies, FGF traps, tyrosine-kinase (TK) inhibitors, allosteric modulators) used to block completely or partially the activities of the FGF-FGFR complexes resulting in clinical drug candidates or tool agents. Comparative analysis of biochemical, pharmacological or clinical data will be discussed for each class of molecules together with some perspectives.
机译:成纤维细胞生长因子受体(FGFRs)和相关配体(FGFs)是经过有效验证的靶标家族,尤其是在癌症疾病中,因其在细胞生长,存活,分化和血管生成中的重要作用而成为治疗干预措施。该专利审查涵盖了用于完全或部分阻断FGF活性的所有不同方法(FGF或FGFR表达的调节剂,抗FGF抗体,抗FGFR抗体,FGF陷阱,酪氨酸激酶(TK)抑制剂,变构调节剂) -FGFR复合物产生临床候选药物或工具制剂。将针对每种分子类型讨论生化,药理或临床数据的比较分析,并提供一些观点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号